20020057.Her2HRpos
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- HYPOXIA+0.340
- COAGULATION+0.280
- ANDROGEN_RESPONSE+0.260
- GLYCOLYSIS+0.240
- ESTROGEN_RESPONSE_LATE+0.230
- ESTROGEN_RESPONSE_EARLY+0.220
- MYOGENESIS+0.220
- PANCREAS_BETA_CELLS+0.190
- UV_RESPONSE_DN+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.450
- E2F_TARGETS-0.410
- G2M_CHECKPOINT-0.390
- MYC_TARGETS_V2-0.390
- MYC_TARGETS_V1-0.330
- DNA_REPAIR-0.290
- ALLOGRAFT_REJECTION-0.260
- MITOTIC_SPINDLE-0.260
- IL6_JAK_STAT3_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518340 | — | F | 0.861 |
| 2 | 20060260.Her2HRpos | — | A | 0.822 |
| 3 | SRR8518184 | — | F | 0.815 |
| 4 | SRR8613790 | — | A | 0.803 |
| 5 | 20030071.Her2HRpos | — | A | 0.802 |
| 6 | SRR35579842 | — | A | 0.800 |
| 7 | SRR8518453 | — | F | 0.799 |
| 8 | TCGA-50-5930-01A-11R-1755-07 | — | cohortA4 | 0.794 |
| 9 | 20020070.LumA | — | A | 0.790 |
| 10 | 20020009.LumA | — | A | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |